litlas
Log inCreate account

Rosane Charlab

Active 1998–2025

40
Papers
20,417
Citations
33
h-index
38
i10-index

Citations

Citations per year for Rosane Charlab1877: 1 citations1930: 1 citations1948: 1 citations1966: 1 citations1973: 1 citations1991: 1 citations1993: 1 citations1994: 1 citations1996: 1 citations1997: 1 citations1998: 1 citations1999: 4 citations2000: 10 citations2001: 283 citations2002: 432 citations2003: 453 citations2004: 409 citations2005: 345 citations2006: 258 citations2007: 252 citations2008: 238 citations2009: 218 citations2010: 214 citations2011: 173 citations2012: 102 citations2013: 123 citations2014: 115 citations2015: 121 citations2016: 114 citations2017: 131 citations2018: 107 citations2019: 272 citations2020: 295 citations2021: 349 citations2022: 291 citations2023: 241 citations2024: 381 citations2025: 224 citations2026: 11 citations1878–1929: no citations, so these years are not shown1931–1947: no citations, so these years are not shown1949–1965: no citations, so these years are not shown1967–1972: no citations, so these years are not shown1974–1990: no citations, so these years are not shown1992: no citations, so this year is not shown1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,040 citing papers, 34% of this breakdownUnited Kingdom: 642 citing papers, 7.2% of this breakdownChina: 595 citing papers, 6.7% of this breakdownGermany: 497 citing papers, 5.6% of this breakdownCanada: 342 citing papers, 3.8% of this breakdownFrance: 333 citing papers, 3.7% of this breakdownItaly: 313 citing papers, 3.5% of this breakdownJapan: 252 citing papers, 2.8% of this breakdownSpain: 238 citing papers, 2.7% of this breakdownAustralia: 223 citing papers, 2.5% of this breakdownSwitzerland: 189 citing papers, 2.1% of this breakdownIndia: 155 citing papers, 1.7% of this breakdown
0%34%Other 23.7%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology55.9%
  • Medicine20.5%
  • Agricultural and Biological Sciences5.2%
  • Immunology and Microbiology4.8%
  • Computer Science3.4%
  • Neuroscience3.3%
  • Other6.9%

Topics

  • Genomics and Phylogenetic Studies5.5%
  • RNA and protein synthesis mechanisms4.3%
  • Chromosomal and Genetic Variations2.8%
  • Genomics and Chromatin Dynamics2.1%
  • Bioinformatics and Genomic Networks2%
  • RNA modifications and cancer1.9%
  • Other81.4%

Coauthors

All papers

Open in search
  1. The Sequence of the Human Genome

    Authors: J. Craig Venter, Mark D. Adams, Eugene W. Myers, Peter W. Li, Richard Mural, Granger G. Sutton, Hamilton O. Smith, Mark Yandell, Cheryl Evans, Robert A. Holt, Jeannine D. Gocayne, Peter G. Amanatides, Richard M. Ballew, Daniel H. Huson, Jennifer R. Wortman, Qing Zhang, Chinnappa D. Kodira, Xiangqun Zheng-Bradley, Lin Chen, Marian Skupski, G. Subramanian, Paul D. Thomas, Jinghui Zhang, George L. Gabor Miklos, Catherine R. Nelson, Samuel Broder, Andrew G. Clark, Joe Nadeau, Victor A. McKusick, Norton D. Zinder, Arnold J. Levine, Richard J. Roberts, Mel I. Simon, Carolyn W. Slayman, Michael W. Hunkapiller, Randall Bolanos, Arthur L. Delcher, Ian Dew, Daniel Fasulo, Michael J. Flanigan, Liliana Florea, Aaron L. Halpern, Sridhar Hannenhalli, Saul Kravitz, Samuel Lévy, Clark Mobarry, Knut Reinert, Karin Remington, Jane Abu-Threideh, Ellen M. Beasley, Kendra Biddick, Vivien Bonazzi, Rhonda Brandon, Michele Cargill, Ishwar Chandramouliswaran, Rosane Charlab, Kabir Chaturvedi, Zuoming Deng, Valentina Di Francesco, Patrick Dunn, Karen Eilbeck, Carlos Evangelista, Andrei Gabrielian, Weiniu Gan, Wangmao Ge, Fangcheng Gong, Zhiping Gu, Ping Guan, Thomas J. Heiman, Maureen E. Higgins, Rui‐Ru Ji, Zhaoxi Ke, Karen A. Ketchum, Zhongwu Lai, Yiding Lei, Zhenya Li, Jiayin Li, Yong Liang, Xiaoying Lin, Fu Lu, Gennady V. Merkulov, Natalia V. Milshina, Helen M. Moore, Ashwinikumar K. Naik, Vaibhav A. Narayan, Beena Neelam, Deborah Nusskern, Douglas B. Rusch, Steven L. Salzberg, Wei Shao, Bixiong Chris Shue, Jing‐Tao Sun, Zhen Yuan Wang, Aihui Wang, Xin Wang, Jian Wang, Ming-Hui Wei, Ron Wides, Chunlin Xiao, Chunhua Yan and 173 more - Science 2001 cited by 13,699

  2. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

    Authors: Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri‐Kordestani, Julia A. Beaver - Clinical Cancer Research 2020 cited by 150

  3. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

    Authors: Julia A. Beaver, Laleh Amiri‐Kordestani, Rosane Charlab, Wei Chen, Todd R. Palmby, Amy Tilley, Jeanne Fourie Zirkelbach, Jingyu Yu, Qi Liu, Liang Zhao, Joyce Z. Crich, Xiao Hong Chen, Minerva Hughes, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Paul G. Kluetz, Geoffrey Kim, Amna Ibrahim, Richard Pazdur, Patricia Cortazar - Clinical Cancer Research 2015 cited by 372

  4. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

    Authors: Jaleh Fallah, Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman, Erik Bloomquist, Rosane Charlab, Salaheldin S. Hamed, Claudia P. Miller, Sarah E. Dorff, Wiley Chambers, Bronwyn D. Mixter, Jeannette Dinin, William F. Pierce, Tiffany K. Ricks, Shenghui Tang, Martha Donoghue, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Julia A. Beaver - Clinical Cancer Research 2022 cited by 171

  5. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

    Authors: Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver - Clinical Cancer Research 2020 cited by 183

  6. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

    Authors: Diana Bradford, Erin Larkins, Sirisha L. Mushti, Lisa Rodríguez, Amy M. Skinner, Whitney S. Helms, Lauren Price, Jeanne Fourie Zirkelbach, Yangbing Li, Jiang Liu, Rosane Charlab, Francisca Reyes Turcu, Dun Liang, Soma Ghosh, Donna Roscoe, Reena Philip, Autumn Zack-Taylor, Shenghui Tang, Paul G. Kluetz, Julia A. Beaver, Richard Pazdur, Marc R. Theoret, Harpreet Singh - Clinical Cancer Research 2020 cited by 167

  7. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

    Authors: Hyon-Zu Lee, Virginia E. Kwitkowski, Pedro L. Del Valle, M. Ricci, Haleh Saber, Bahru Habtemariam, Julie Bullock, Erik Bloomquist, Yuan Li Shen, Xiao-Hong Chen, Janice Brown, Nitin Mehrotra, Sarah E. Dorff, Rosane Charlab, Robert C. Kane, Edvardas Kaminskas, Robert Justice, Ann T. Farrell, Richard Pazdur - Clinical Cancer Research 2015 cited by 355

  8. FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Authors: Katie Chon, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Stephanie Aungst, Emily Wearne, Sriram Subramaniam, Yangbing Li, Jiang Liu, Jielin Sun, Rosane Charlab, Hong Zhao, Banu Saritas-Yildirim, Rama Kamesh Bikkavilli, Soma Ghosh, Reena Philip, Julia A. Beaver, Harpreet Singh - Clinical Cancer Research 2023 cited by 56

  9. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

    Authors: Kelly J. Norsworthy, Flora Mulkey, Emma Scott, Ashley F. Ward, Donna Przepiorka, Rosane Charlab, Sarah E. Dorff, Albert Deisseroth, Dickran Kazandjian, Rajeshwari Sridhara, Julia A. Beaver, Ann T. Farrell, R. Angelo de Claro, Richard Pazdur - Clinical Cancer Research 2020 cited by 104

  10. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

    Authors: Sandra J. Casak, Shan Pradhan, Lola A. Fashoyin-Aje, Yi Ren, Yuan-Li Shen, Yuan Xu, Edwin Chiu Yuen Chow, Ye Xiong, Jeanne Fourie Zirklelbach, Jiang Liu, Rosane Charlab, William F. Pierce, Nataliya Fesenko, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery - Clinical Cancer Research 2022 cited by 64

  11. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

    Authors: Janice Kim, Diana Bradford, Erin Larkins, Lee H. Pai-Scherf, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Emily Wearne, Whitney S. Helms, Amal Ayyoub, Youwei Bi, Jielin Sun, Rosane Charlab, Jiang Liu, Hong Zhao, Dun Liang, Soma Ghosh, Reena Philip, Richard Pazdur, Marc R. Theoret, Julia A. Beaver, Harpreet Singh - Clinical Cancer Research 2021 cited by 100

  12. The Genome Sequence of the Malaria Mosquito Anopheles gambiae

    Authors: Robert A. Holt, G. Subramanian, Aaron L. Halpern, Granger G. Sutton, Rosane Charlab, Deborah Nusskern, Patrick Wincker, Andrew G. Clark, José M. C. Ribeiro, Ron Wides, Steven L. Salzberg, Brendan Loftus, Mark Yandell, William H. Majoros, Douglas B. Rusch, Zhongwu Lai, Cheryl Kraft, Josep F. Abril, Véronique Anthouard, Peter Arensburger, Peter W. Atkinson, Holly Baden, Véronique de Berardinis, Danita Baldwin, Vladimı́r Beneš, Jim Biedler, Claudia Blass, Randall Bolanos, Didier Boscus, Mary Barnstead, Shuang Cai, Kabir Chatuverdi, George K. Christophides, Mathew A. Chrystal, Michèle Clamp, Anibal Cravchik, Val Curwen, Ali Dana, Art L. Delcher, Ian Dew, Cheryl Evans, Michael J. Flanigan, Anne Grundschober-Freimoser, Lisa Friedli, Zhiping Gu, Ping Guan, Roderic Guigó, Maureen E. Hillenmeyer, Susanne L. Hladun, James R. Hogan, Young Seok Hong, Jeffrey P. Hoover, Olivier Jaillon, Zhaoxi Ke, Chinnappa D. Kodira, E. B. Kokoza, Anastasios C. Koutsos, Ivica Letunić, Alex Levitsky, Yong Liang, Jing‐Jer Lin, Neil F. Lobo, John Lopez, Joel A. Malek, Tina C. McIntosh, Stephan Meister, Jason Miller, Clark Mobarry, Emmanuel Mongin, Sean D. Murphy, David A. O’Brochta, Cynthia Pfannkoch, Rong Qi, Megan A. Regier, Karin Remington, Hongguang Shao, Maria V. Sharakhova, Cynthia D. Sitter, Jyoti Shetty, Thomas J. Smith, Renee Strong, Jing‐Tao Sun, Dana Thomasová, Lucas Q. Ton, Pantelis Topalis, Zhijian Tu, Maria Unger, Brian P. Walenz, Aihui Wang, Jian Wang, Mei Wang, Xuelan Wang, Kerry J. Woodford, Jennifer R. Wortman, Martin Wu, Alison Yao, Evgeny M. Zdobnov, Zhang HongYu, Qi Zhao, Shaying Zhao and 22 more - Science 2002 cited by 2,045

  13. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

    Authors: Timil H. Patel, Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Robert N. Schuck, Yangbing Li, Xinyuan Zhang, Jeanne Fourie Zirkelbach, Rosane Charlab, Jiang Liu, Yuching Yang, Steven J. Lemery, Richard Pazdur, Marc R. Theoret, Lola A. Fashoyin‐Aje - Clinical Cancer Research 2022 cited by 57

  14. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

    Authors: Kelly J. Norsworthy, Lola Luo, Vicky Hsu, Ramadevi Gudi, Sarah E. Dorff, Donna Przepiorka, Albert Deisseroth, Yuan Li Shen, Christopher M. Sheth, Rosane Charlab, Gene M. Williams, Kirsten B. Goldberg, Ann T. Farrell, Richard Pazdur - Clinical Cancer Research 2019 cited by 136

  15. FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

    Authors: Sonia Singh, Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Lingshan Wang, Hong Zhao, Ye Xiong, Jiang Liu, Rosane Charlab, Jeffrey Kraft, Sachia G. Khasar, Claudia P. Miller, Donna R. Rivera, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver, Harpreet Singh, Martha Donoghue - Clinical Cancer Research 2023 cited by 44

  16. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer

    Authors: Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton, Laura L. Fernandes, Shenghui Tang, Hisani N. Horne, Jinzhong Liu, Chao Liu, Sarah J. Schrieber, Jingyu Yu, Pengfei Song, William F. Pierce, Kim J. Robertson, Todd R. Palmby, Haw-Jyh Chiu, Eunice Y. Lee, Reena Philip, Robert N. Schuck, Rosane Charlab, Anamitro Banerjee, Xiao Hong Chen, Xing Wang, Kirsten B. Goldberg, Rajeshwari Sridhara, Geoffrey Kim, Richard Pazdur - Clinical Cancer Research 2017 cited by 164

  17. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy

    Authors: Gwynn Ison, Lynn Howie, Laleh Amiri‐Kordestani, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Vadryn Pierre, Rosane Charlab, Anuradha Ramamoorthy, Pengfei Song, Fang Li, Jingyu Yu, Wimolnut Manheng, Todd R. Palmby, Soma Ghosh, Hisani N. Horne, Eunice Y. Lee, Reena Philip, Kaushalkumar Dave, Xiao Hong Chen, Sharon L. Kelly, Kumar G. Janoria, Anamitro Banerjee, Okponanabofa Eradiri, Jeannette Dinin, Kirsten B. Goldberg, William F. Pierce, Amna Ibrahim, Paul G. Kluetz, Gideon M. Blumenthal, Julia A. Beaver, Richard Pazdur - Clinical Cancer Research 2018 cited by 131

  18. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer

    Authors: Mitchell S. Anscher, Elaine Chang, Xin Gao, Yutao Gong, Chana Weinstock, Erik Bloomquist, Oluseyi Adeniyi, Rosane Charlab, Sarah Zimmerman, Maritsa Serlemitsos-Day, Ning Yang, Ruth Mayrosh, Barbara K. Fuller, Ann Marie Trentacosti, Pamela Gallagher, Karen E. Bijwaard, Reena Philip, Soma Ghosh, Frances Fahnbulleh, Felicia Diggs, Shaily Arora, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri‐Kordestani, Richard Pazdur, Amna Ibrahim, Julia A. Beaver - The Oncologist 2020 cited by 70

  19. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

    Authors: Ashley Woods, Kelly J. Norsworthy, Xin Wang, Jonathon Vallejo, Edwin C.Y. Chow, Ruo‐Jing Li, Jielin Sun, Rosane Charlab, Xiling Jiang, Richard Pazdur, Marc R. Theoret, R. Angelo de Claro - Clinical Cancer Research 2023 cited by 24

  20. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer

    Authors: Melanie Royce, Christy Osgood, Anup Amatya, Mallorie H. Fiero, C.J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen A. Clouse, Vicky Borders‐Hemphill, Lindsey Brown, Candace Gomez-Broughton, Li Zhong, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi‐Ming Tu, Bellinda L. King‐Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani - Clinical Cancer Research 2021 cited by 39

  21. Comparative Genome and Proteome Analysis of Anopheles gambiae and Drosophila melanogaster

    Authors: Evgeny M. Zdobnov, Christian von Mering, Ivica Letunić, David Torrents, Mikita Suyama, Richard R. Copley, George K. Christophides, Dana Thomasová, Robert A. Holt, G. Subramanian, Hans-Michael Mueller, George Dimopoulos, John H. Law, Michael A. Wells, Ewan Birney, Rosane Charlab, Aaron L. Halpern, E. B. Kokoza, Cheryl Kraft, Zhongwu Lai, Suzanna Lewis, Christos Louis, Carolina Barillas‐Mury, Deborah Nusskern, Gerald M. Rubin, Steven L. Salzberg, Granger G. Sutton, Pantelis Topalis, Ron Wides, Patrick Wincker, Mark Yandell, Frank H. Collins, José M. C. Ribeiro, William M Gelbart, Fotis C. Kafatos, Peer Bork - Science 2002 cited by 551

  22. FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

    Authors: Shruti U. Gandhy, Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Sriram Subramaniam, Hong Zhao, Miao Zhao, Youwei Bi, Guan‐Sheng Liu, Jianghong Fan, Oluseyi Adeniyi, Rosane Charlab, Dubravka Kufrin, Matthew D. Thompson, Kristin Jarrell, Doris Auth, Steven J. Lemery, Richard Pazdur, Paul G. Kluetz, Lola A. Fashoyin‐Aje - Clinical Cancer Research 2023 cited by 20

  23. Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer

    Authors: Sean Khozin, Chana Weinstock, Gideon M. Blumenthal, Joyce Cheng, Kun He, Luning Zhuang, Hong Zhao, Rosane Charlab, Ingrid Fan, Patricia Keegan, Richard Pazdur - Clinical Cancer Research 2016 cited by 84

  24. Purification, Cloning, and Expression of a Novel Salivary Anticomplement Protein from the Tick, Ixodes scapularis

    Authors: Jesús G. Valenzuela, Rosane Charlab, Thomas N. Mather, José M. C. Ribeiro - Journal of Biological Chemistry 2000 cited by 266